Gitnux/Report 2026

Chinese Pharmaceutical Industry Statistics

297Statistics
86Sources
12Sections
1Visuals
44mRead
Chinese Pharmaceutical Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The chinese pharmaceutical industry at a glance

China’s pharmaceutical market reached RMB1,781.6 billion in 2024 and is shifting toward innovative medicines, biologics, international licensing and higher-value manufacturing despite pricing pressure from centralized procurement.

RMB1,781.6B[1]
Market size, 2024
6.3%[1]
Forecast CAGR, 2024–2032
4.5%[78]
Largest company share, 2025
$239.94B[79]
Chemical drug exports, 2025
Market size
China’s pharmaceutical market was RMB1,781.6 billion in 2024, measured by sales revenue. A separate market study estimated the 2024 market at RMB1,699.1 billion, reflecting differences in market definitions and coverage.[1][3]
Forecast & CAGR
The market is projected to increase from RMB1,781.6 billion in 2024 to RMB2,914.9 billion in 2032, implying a 6.3% CAGR. Innovative drugs are forecast to grow at 8.3% annually, compared with 2.7% for generic drugs and biosimilars.[1]
Market share & regions
In 2024 pharmaceutical distribution sales, Guangdong led with RMB314.75 billion, followed by Beijing at RMB236.01 billion, Shanghai at RMB228.18 billion, Jiangsu at RMB227.83 billion and Zhejiang at RMB200.32 billion. These five regions together represented approximately 41.0% of the national distribution total of RMB2,947.03 billion.[80]
Segmentation
The market is divided into innovative drugs and generic drugs and biosimilars. In 2024, innovative drugs generated RMB1,074.3 billion, or about 60.3% of the total, while generics and biosimilars generated RMB707.3 billion, or about 39.7%.[1]
Key players & concentration
China’s pharmaceutical manufacturing base remains fragmented: Yangtze River Pharmaceutical Group was the largest company in 2025 but accounted for only 4.5% of total industry production value. Major distribution groups include Sinopharm, Shanghai Pharmaceuticals and China Resources Pharmaceutical.[78][81]
Pricing
Centralized procurement continues to compress prices for selected medicines. By July 2025, China’s National Healthcare Security Administration had required price adjustments for 726 medicines across various specifications, involving 566 companies.[15]
Trends, drivers & challenges
Growth is being supported by innovative oncology and obesity treatments, reimbursement of new medicines and stronger hospital infrastructure. Constraints include volume-based procurement, cost-conscious hospital payment reforms and demographic decline expected to begin from 2026.[82]
Consumer behavior & competition
Competition is moving from predominantly low-cost generics toward innovative drugs, biologics and differentiated therapies. In 2024, biologics were forecast in one industry study to grow at a 15.8% CAGR during 2023–2026, compared with 3.6% for chemical pharmaceuticals.[3]
M&A
China’s pharmaceutical deal market remained active in 2025, with 78 mergers, acquisitions and strategic investment transactions recorded. Out-licensing also expanded sharply: disclosed licensing value reached approximately $135.7 billion across 157 transactions, compared with $51.9 billion across 94 transactions in 2024.[83]
Regulation
China’s revised implementing provisions for the Drug Administration Law were adopted on December 31, 2025, strengthening whole-life-cycle supervision and supporting innovative drug development. A 2025 reform guideline targets more efficient review and approval and a more developed regulatory framework by 2027.[84][15]
Latest news
In September 2026, China released a pharmaceutical-industry five-year plan targeting global leadership in biomedical research, development and application by 2030. Pharmaceutical and related biomedical sectors produced nearly RMB6 trillion in 2025 and are expected to exceed RMB10 trillion by 2030.[15]
report visual · Projection

Size of the anti-influenza drugs market in the PRC (China)

Size of the anti-influenza drugs market in the PRC grew from 3.2 RMB billion in 2020 to 6.7 RMB billion in 2024.

3.2 RMB billion
Start
+20.29%
CAGR · 4y
6.7 RMB billion
Projected
20202024
source-verifiedhkexnews.hk2024

03 Statistics

Technology & Innovation

AI in the chinese pharmaceutical industry

  • China’s pharmaceutical and medical-device R&D expenditure reached RMB261.2 billion in 2023, supporting AI-enabled drug-development capabilities.[1]
  • China had more than 1,250 novel drugs entering development in 2024, according to an analysis of the country’s biopharmaceutical innovation ecosystem.[2]

Automation in the chinese pharmaceutical industry

  • CSPC Pharmaceutical Group invested RMB1 billion in its intelligent oral-solid-dose plant, which began operating in Hebei in June 2023.[3]
  • Shanghai Lingang production base became a national intelligent-manufacturing demonstration factory and Shanghai benchmark intelligent factory by 2023.[3]
  • China’s pharmaceutical traceability platform covered 98% of pharmaceutical manufacturers and 100% of vaccine and blood-product manufacturers in 2025.[1]
  • CSPC’s OUYI Plant 100 incorporated full-process automatic logistics, automated warehousing and dark-factory automation by 2023.[3]
  • Qidu Pharma’s Chinese smart factory automated 80% of processes, including production execution, control and data collection, according to a 2026 sector review.[4]

Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)

  • 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[5]
  • 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[6]
  • 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[7]
  • 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[7]
  • 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[5]

Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)

  • 55% of biopharma AI adopters reported using AI in process development in 2024.[8]
  • 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[9]
  • 70% of global biopharma respondents had adopted an R&D data platform in 2023.[9]
  • 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[10]
  • 63% of global biopharma respondents had adopted robotics and automation in 2023.[9]

Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)

  • 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[11]
  • 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[8]
  • 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[12]
  • 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[8]
  • 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[9]

Big Data in the pharmaceuticals and biotech sector (sector benchmark)

  • 48% of pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[6]
  • 49% of clinical-research survey respondents reported using AI and big-data analytics in drug development in 2024.[7]
  • 33% of biopharma survey respondents reported using data lakes in day-to-day operations in 2021.[11]
  • 55% of large pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[6]
  • 68% of pharmaceutical companies surveyed planned to use advanced analytics in 2024.[13]
  • 43% of small and midsize pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[6]

Blockchain in the chinese pharmaceutical industry

  • The platform connected 200,000 retail pharmacies in China in 2025.[1]
  • China’s blockchain-enabled medicine platform connected more than 10,000 wholesale enterprises in 2025.[1]

04 Statistics

Data & Analytics

Business intelligence in the chinese pharmaceutical industry

  • 9,000 professionals comprised Hutchmed’s dedicated in-house sales and marketing team in China at December 31, 2024.[14]
  • RMB20 million in annual main-business turnover is the Chinese government’s threshold for a large-scale enterprise covered by the pharmaceutical digital-transformation plan.[15]
  • 2030 is the target year for essentially full digital-intelligent-transformation coverage among large-scale pharmaceutical enterprises in China.[15]
  • 130,000 traditional-Chinese-medicine SKU types were supplied by YSB to downstream customers in China in 2024.[16]
  • 22,000 hospitals and more than 200,000 offline retail pharmacies were covered by Hutchmed’s Chinese commercial network at December 31, 2024.[14]
  • RMB2,073 million was YSB’s 2024 sales amount for traditional-Chinese-medicine decoction pieces supplied to downstream customers.[16]

Data analytics in the chinese pharmaceutical industry

  • 1 annual-report and periodic-safety-update-report generation and export function was described in Da Ren Tang’s drug-vigilance system in 2024.[17]
  • 3,410 drug clinical trials were registered in China in 2022.[15]
  • 3,358 drug clinical trials were registered in China in 2021, providing a national dataset for pharmaceutical development analytics.[15]
  • 4,300 drug clinical trials were registered in China in 2023, according to the cited industry report.[15]
  • 27,972 drug clinical trials had been registered on China’s drug-trial platform by December 31, 2024.[18]
  • 56.5% of cell- and gene-therapy trials in China in 2024 were in Phase I.[19]

Data Quality in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[20]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[20]
  • Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[21]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[20]
  • Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[20]

Data Governance in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[22]
  • Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[21]
  • Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[23]
  • Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[22]
  • Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[22]

KPIs in the chinese pharmaceutical industry

  • 36.2% was the share of global active originator companies represented by China-headquartered companies in 2024.[24]
  • 62.8% was YSB’s year-on-year increase in traditional-Chinese-medicine decoction-piece sales in China in 2024.[16]
  • 26.1% was the increase in China’s registered drug clinical trials from 2022 to 2023.[18]
  • 48.1% was China’s share of the countries listed in the source’s comparison of global new-drug clinical trials in 2024.[24]
  • 100% was CR Sanjiu’s product- and service-complaint handling rate in China in 2024.[25]
  • 11.6% was the year-on-year growth of China’s traditional-Chinese-medicine industrial chain in 2024.[26]

05 Statistics

Strategy & Growth

Growth in the chinese pharmaceutical industry

  • Hengrui’s total revenue rose from RMB27.98 billion in 2024 to RMB31.63 billion in 2025.[1]
  • 91 pharmaceutical-sector deals were recorded in China in 2024, with total deal value of US$4.4 billion.[4]
  • China’s pharmaceutical market sales revenue was projected to grow from RMB1,781.6 billion in 2024 to RMB2,914.9 billion in 2032, implying a 6.3% CAGR.[1]
  • China’s pharmaceutical-sector deal volume increased from 85 transactions in 2023 to 91 transactions in 2024.[4]
  • 7 innovative drugs or biosimilars and 79 generic-drug varieties were approved domestically or internationally by the reporting group in 2024.[1]
  • China’s innovative-drug market was projected to reach RMB753.4 billion in 2024.[18]

Differentiation in the chinese pharmaceutical industry

  • 3 U.S. patent applications and 18 PCT applications were included among 220 patent applications filed by the reporting group’s pharmaceutical manufacturing segment in 2024.[1]
  • 18 Hengrui research papers achieved high-impact status in 2025, defined by an impact factor of at least 30 in oncology or 20 in non-oncology.[3]
  • 40 innovative drug candidates were covered by more than 60 clinical trials under investigation at Biocytogen in 2024.[3]
  • 3 key innovative drug candidates entered phase III clinical development at Biocytogen in 2024.[3]
  • 4 innovative drug candidates were in the reporting company’s pipeline at December 31, 2025, including oncology and ophthalmology programs.[3]
  • 986 issued invention patents were held by Hengrui in Greater China at the end of 2025.[3]

Mergers and acquisitions in the chinese pharmaceutical industry

  • US$4.4 billion was the total value of China pharmaceutical-sector deals in 2024.[4]
  • 32 pharmaceutical-sector deals were recorded in China in the third quarter of 2024.[4]
  • 85 pharmaceutical-sector deals were recorded in China in 2023.[4]
  • 17 pharmaceutical-sector deals were recorded in China in the fourth quarter of 2024.[4]
  • 38.4% was the increase in China pharmaceutical-sector deal value in 2024, driven by two major acquisitions.[4]
  • 16 pharmaceutical-sector deals were recorded in China in the second quarter of 2024.[4]

Strategic partnerships in the chinese pharmaceutical industry

  • 34 Chinese pharmaceutical license-out deals occurred in the first half of 2024, according to industry statistics cited by Hengrui.[27]
  • 70 out-licensing transactions were completed by Chinese companies in 2024.[28]
  • US$4.2 billion was the total upfront payment value in Chinese out-licensing transactions in 2024.[28]
  • 19 overseas in-licensing transactions were completed by Chinese companies in 2024.[28]
  • US$40 billion was the total disclosed value of Chinese out-licensing transactions in 2024.[28]
  • 136 licensing transactions involving China were recorded in 2024, including in-licensing and out-licensing agreements.[28]

06 Statistics

People & Workforce

Hiring in the chinese pharmaceutical industry

  • Wanhan Pharmaceuticals employed a 70-member R&D team in Zhongshan in 2026.[29]
  • Pudong’s biomedical-industry talent departure rate was 15.6% in 2024.[30]
  • Chinese biotech companies planned 68% growth in R&D staffing in 2021 versus 2020.[31]
  • Pudong had more than 20 academicians among its biomedical professionals and international experts by 2025.[30]
  • Pudong attracted more than 140,000 biomedical professionals by 2025, including 22,000 returnees and foreign experts.[30]

Employee retention in the chinese pharmaceutical industry

  • Ascentage Pharma’s turnover rate was 13.83% among employees aged 30 or below in 2021.[32]
  • Pudong’s biomedical talent departure rate was 15.6% in 2024, below its 16.3% inflow rate.[30]
  • Ascentage Pharma’s total employee turnover rate was 10.6% in mainland China in 2021.[32]
  • China’s healthcare market had an average attrition rate of 25%–30% in 2021, according to Sanofi Greater China.[33]
  • Ascentage Pharma’s turnover rate was 12.42% among employees aged 30–50 in 2021.[32]

Remote Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[34]
  • Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[35]
  • Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[34]
  • Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[36]

Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[37]
  • Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[36]
  • Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[38]
  • Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[4]

Upskilling in the chinese pharmaceutical industry

  • Sinopharm employees completed an average of 64.9 training hours in 2024.[1]
  • Ascentage Pharma’s mainland-China employee training coverage reached 100% in 2025.[1]
  • Livzon Pharmaceutical employees completed an average of 102.3 training hours in 2024.[16]
  • China Resources Sanjiu achieved 98.68% employee training coverage in 2024.[25]
  • China Resources Sanjiu invested RMB10.432 million in employee training in 2024.[25]

Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)

  • Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[39]
  • At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[40]
  • Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[39]
  • Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[39]

DEI in the chinese pharmaceutical industry

  • Ascentage Pharma’s 2025 trained workforce comprised 74.71% junior staff, 21.12% middle management and 4.17% senior management.[1]
  • Ascentage Pharma’s average training hours were 7.11 for men and 7.61 for women in 2024.[41]
  • Huadong Medicine’s 2024 training participants were 51.07% female and 48.93% male.[42]

07 Statistics

Customer & Sales

Customer experience in the chinese pharmaceutical industry

  • 54 was the 2024 digital customer-experience score reported by Chinese oncology HCPs interacting with pharmaceutical companies.[43]
  • 64 was the 2024 non-digital customer-experience score reported by Chinese diabetologists interacting with pharmaceutical companies.[43]
  • China’s pharmaceutical HCP customer-experience score fell by 6 points in 2024, according to the CXQ® country assessment.[43]
  • 215,000 drug SKUs were available on Fangzhou’s Chinese online retail pharmacy platform at December 31, 2024, supporting product-search and choice experience.[1]

Customer retention in the chinese pharmaceutical industry

  • 85.4% was Fangzhou’s repeat-purchase rate among paying users in China for the twelve months ended June 30, 2025.[16]
  • 66.2% was Fangzhou’s 90-day patient repurchase rate for Chinese prescription-drug users in 2024.[26]
  • 63.7% was Fangzhou’s 90-day patient repurchase rate for Chinese prescription-drug users in 2023.[26]
  • 4.7% of users repurchased medication through a Chinese traditional-medicine internet-hospital dispensing clinic in the reported study cohort.[44]
  • 85.8% was Fangzhou’s repeat-purchase rate among paying users in China for the twelve months ended June 30, 2024.[1]

Customer acquisition in the chinese pharmaceutical industry

  • 32.6% was the 2021 active-user-to-paying-user conversion rate on Fangzhou’s Chinese H2H service platform.[1]
  • 52.8 million registered users were recorded on Fangzhou’s Chinese platform at June 30, 2025.[16]
  • 36.2% was the 2023 active-user-to-paying-user conversion rate on Fangzhou’s Chinese H2H service platform.[1]
  • 42.9% was the 2022 active-user-to-paying-user conversion rate on Fangzhou’s Chinese H2H service platform.[1]
  • 45.6 million registered users were recorded on Fangzhou’s Chinese platform at June 30, 2024.[1]

Customer loyalty in the chinese pharmaceutical industry

  • 85.4% was the repeat-purchase rate among Fangzhou’s paying users in China for the twelve months ended June 30, 2025.[16]
  • 81.8% of Fangzhou’s Chinese gross merchandise value came from prescription drugs in the six months ended June 30, 2024.[1]
  • 81.7% of Fangzhou’s Chinese gross merchandise value came from prescription drugs in the six months ended June 30, 2025.[16]
  • 85.8% was the repeat-purchase rate among Fangzhou’s paying users in China for the twelve months ended June 30, 2024.[1]

08 Statistics

Marketing & Brand

Marketing in the chinese pharmaceutical industry

  • RMB584.7 billion was total healthcare marketing spending by pharmaceutical and medical-device companies in China in 2018.[1]
  • RMB632.0 billion was total healthcare marketing spending by pharmaceutical and medical-device companies in China in 2019.[1]
  • RMB679.7 billion was total healthcare marketing spending by pharmaceutical and medical-device companies in China in 2020.[1]

Digital marketing in the chinese pharmaceutical industry

  • RMB8.1 billion was digital healthcare marketing spending by pharmaceutical and medical-device companies in China in 2019.[1]
  • 2.2% was digital healthcare marketing’s share of total healthcare marketing spending by pharmaceutical and medical-device companies in China in 2020.[1]
  • RMB4.4 billion was digital healthcare marketing spending by pharmaceutical and medical-device companies in China in 2018.[1]
  • RMB57.0 billion was forecast digital healthcare marketing spending by pharmaceutical and medical-device companies in China in 2023.[1]
  • RMB80.4 billion was forecast digital healthcare marketing spending by pharmaceutical and medical-device companies in China in 2024.[1]

Branding in the chinese pharmaceutical industry

  • 53% was the average awareness of Chinese pharmaceutical brands in Brand Finance’s 2024 assessment.[45]
  • 88% of Chinese consumers associated traditional Chinese-medicine brands with natural ingredients in the 2024 assessment.[45]
  • 78% of Chinese consumers associated traditional Chinese-medicine brands with safety and absence of side effects in the 2024 assessment.[45]
  • 35% was the average familiarity with Chinese pharmaceutical brands in Brand Finance’s 2024 assessment.[45]
  • 91% was Yunnan Baiyao’s consumer familiarity in China in the 2024 Brand Finance assessment.[45]

Social media in the chinese pharmaceutical industry

  • 530 million daily active users used short-video platforms in China by April 2024.[46]
  • 51.4 billion hours were spent on short-video platforms in China by users during the measured April 2024 period.[46]
  • More than 40,000 hours of short-video use per day were represented by China’s reported 530 million daily active users and average usage figures in April 2024.[46]
  • 1.03 billion monthly active users used short-video platforms in China by April 2024, creating a large channel for pharmaceutical-brand and health education content.[46]

Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)

  • 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[47]
  • 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[48]
  • 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[49]
  • 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[48]
  • 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[49]

09 Statistics

Operations & Execution

Operational efficiency in the chinese pharmaceutical industry

  • RMB14,729.6 billion was China’s 2024 pharmaceutical-manufacturing operating cost, up 2.0% from 2023.[50]
  • 62 days was CSPC Pharmaceutical Group’s 2024 trade-receivables turnover period in China-related sales, compared with 63 days in 2023.[16]
  • RMB29,762.7 billion was the 2024 operating revenue of China’s above-designated-size pharmaceutical industry, broadly unchanged from 2023.[51]
  • RMB4,535 million was CSPC Pharmaceutical Group’s cash inflow from operating activities in 2024, compared with RMB4,179 million in 2023.[16]
  • RMB342.07 billion was the 2024 total profit of China’s above-designated-size pharmaceutical manufacturing industry, down 1.1% year on year.[1]

Quality management in the chinese pharmaceutical industry

  • 6,254 provincial-level medical-device GMP inspectors were qualified in China by the end of 2024, illustrating the breadth of regulatory quality infrastructure serving pharmaceutical manufacturers.[52]
  • 2,657 chemical-drug batches were sampled at production sites in China’s 2024 national drug-quality program.[19]
  • 4,284 provincial-level cosmetics inspectors were qualified in China by the end of 2024 as part of the wider provincial product-quality inspection system.[52]
  • 7,793 provincial-level drug GMP inspectors were qualified in China by the end of 2024.[52]
  • 741 chemical-drug batches were sampled at points of use in China’s 2024 national drug-quality program.[19]

Supply chain in the chinese pharmaceutical industry

  • 90.41% of drugs in a Chinese national shortage-monitoring sample were listed as national essential medicines.[53]
  • 42.04% of drugs in the Chinese shortage-monitoring sample were medicines for children.[53]
  • 89.6% was the mean monthly overall delivery rate for monitored drugs in China after national implementation of the shortage policy examined in the study.[54]
  • 14.70% of drugs in the Chinese shortage-monitoring sample were medicines for rare diseases.[53]
  • 95.10% of drugs in the Chinese shortage-monitoring sample were included in the national medical-insurance system.[53]

Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)

  • 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[55]
  • 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[56]
  • 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[6]
  • 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[57]
  • 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[6]

10 Statistics

Finance & Pricing

Pricing strategy in the chinese pharmaceutical industry

  • 53% was the average price reduction in China’s second national centralized drug-procurement batch reported in a hospital implementation study.[54]
  • 98% was the highest price reduction reported across the first eight rounds of China’s national volume-based procurement.[58]
  • 52% was the approximate average price reduction for 45 products in China’s fourth national volume-based pharmaceutical-procurement round.[3]
  • 93% was the maximum price reduction recorded for a product in China’s second national centralized drug-procurement batch.[54]
  • 36.24% was the estimated price reduction associated with China’s volume-price contract initiative in public hospitals.[18]

Cost reduction in the chinese pharmaceutical industry

  • 37% was the estimated first-year public-procurement spending reduction after observed market-share shifts toward winning products in China’s national volume-based procurement study.[59]
  • 50% was the approximate average reduction in drug-procurement prices after China’s first seven national volume-based-procurement batches.[54]
  • 2.0% was the 2024 increase in operating costs for China’s pharmaceutical manufacturing industry, despite broadly flat revenue.[50]
  • 1.741 million smallest formulation units per month was the estimated decline in purchase-order volume after transparent online open procurement in Ningxia, China.[18]
  • 0.012 yuan per month was the estimated monthly decline in the average purchased-medicine price after transparent online open procurement in Ningxia, China.[18]

Profitability in the chinese pharmaceutical industry

  • RMB4,328.035 million was CSPC Pharmaceutical Group’s 2024 profit attributable to company owners.[16]
  • 47.77% was Shanghai Fosun Pharmaceutical’s 2024 gross margin.[3]
  • RMB20,298.711 million was CSPC Pharmaceutical Group’s 2024 gross profit.[16]
  • 72.6% was China Medical System Holdings’ 2024 gross-profit margin, down from 76.2% in 2023.[16]
  • RMB2,780 million was Shanghai Fosun Pharmaceutical’s 2024 operating profit.[3]

Financial planning in the chinese pharmaceutical industry

  • 62 days was CSPC Pharmaceutical Group’s 2024 trade-receivables turnover period, an indicator relevant to working-capital planning.[16]
  • RMB2,529.85 billion was China’s 2024 pharmaceutical-manufacturing operating revenue used as an industry-scale planning baseline.[1]
  • RMB2,780 million was Shanghai Fosun Pharmaceutical’s 2024 operating profit available for investment, financing and shareholder-allocation decisions.[3]
  • RMB4,535 million was CSPC Pharmaceutical Group’s 2024 operating-activity cash inflow, up from RMB4,179 million in 2023.[16]
  • 63 days was CSPC Pharmaceutical Group’s 2023 trade-receivables turnover period, against which its 2024 working-capital performance was reported.[16]

11 Statistics

Product & Service

Product development in the chinese pharmaceutical industry

  • 4,900 drug clinical trials were registered in China in 2024, including trials sponsored by domestic and overseas organizations.[19]
  • 177 Chinese pharmaceutical companies conducted 691 U.S. clinical trials for 350 original innovative drugs between 2007 and 2023.[18]
  • 378 China-headquartered originator companies had active innovative-drug research programs in 2024, representing 36.2% of the global total.[24]
  • 1,247 novel chemical drugs were approved for clinical trials in China in 2024, up from 493 in 2019.[2]
  • 1,709 next-generation products were in development in China in January 2024, accounting for 39% of the country’s innovative-drug pipeline.[60]

Product lifecycle in the chinese pharmaceutical industry

  • 89 drugs already marketed overseas but not yet in China were approved in China in 2024, including 64 first-time approvals and 25 added indications.[19]
  • 439 new-drug applications were concluded by China’s drug regulator in 2024.[19]
  • 3,011 investigational new-drug applications were concluded by China’s drug regulator in 2024.[19]
  • 4,580 chemical-drug ANDA applications were recorded in China in 2025, compared with 4,768 in 2024.[19]
  • 55 rare-disease drugs were approved in China in 2024, with 20 receiving priority review and approval.[19]

After-sales in the chinese pharmaceutical industry

  • 22,000 hospitals were covered by a Chinese pharmaceutical company’s sales network as of December 31, 2024.[14]
  • 117 product- and service-related complaints were received by CR Sanjiu in China in 2024.[25]
  • 100% was CR Sanjiu’s customer-service satisfaction rate in China in 2024.[25]
  • About 70% was the reach rate of CR Sanjiu’s headquarters cybersecurity education activities in 2024.[25]
  • 24 hours per day was the availability of Sino Biopharmaceutical’s customer-service hotline in 2024.[1]

Value proposition in the chinese pharmaceutical industry

  • RMB23.7 billion in social benefits are expected from Roche innovative drugs in China between 2024 and 2032.[61]
  • RMB9.5 billion in social benefits were generated in China by Roche innovative drugs from 2019 through 2023, according to the China Development Research Foundation analysis.[61]
  • 19.8% was the increase in China’s total health expenditure between 2021 and 2023.[17]
  • 27.7% was personal health expenditure’s share of China’s total health costs in 2020.[26]
  • 60% of savings from generic-drug procurement was allocated by China’s National Healthcare Security Administration to innovative drugs on the reimbursement list from 2019 through the first quarter of 2023.[62]

12 Statistics

Sustainability & Ethics

Sustainability in the chinese pharmaceutical industry

  • 100% of China Shineway’s 3,220 employees and board members received anti-corruption training in 2024.[3]
  • 0.20 tonnes of CO2e per RMB10,000 of revenue was TOT BIOPHARM’s greenhouse-gas intensity in 2024 in China.[1]
  • 22,482 tonnes of CO2e were emitted by TOT BIOPHARM in 2024 across Scope 1 and Scope 2 operations in China.[1]
  • 317 China Shineway suppliers were assessed for environmental impact in 2024.[3]
  • 13 China Shineway suppliers had significant actual or potential negative social impacts in 2024.[3]

ESG in the chinese pharmaceutical industry

  • 45% of Sino Biopharmaceutical’s board members were independent directors in 2024.[63]
  • Hansoh Pharmaceutical Group received an S&P Global ESG Score of 62 in the 2023 Sustainability Yearbook.[64]
  • 53,298 hours of responsible-marketing training were delivered by Sino Biopharmaceutical in 2024.[63]
  • 3.928 was the mean ESG-performance score for Chinese pharmaceutical businesses in a 2015–2021 sample of listed companies.[65]
  • 100% of Sino Biopharmaceutical management and employees in key positions were covered by anti-corruption training in 2024.[63]

Ethics in the chinese pharmaceutical industry

  • 1,449 China Shineway technical frontline workers received anti-corruption training in 2024.[3]
  • 11 anti-commercial-bribery and anti-corruption training sessions were held by Sichuan Kelun Pharmaceutical in 2024.[66]
  • 100% of Sichuan Kelun Pharmaceutical employees were covered by anti-commercial-bribery and anti-corruption training in 2024.[66]
  • 7 China Shineway board members received anti-corruption training in 2024, representing 100% coverage.[3]
  • 724 China Shineway non-technical frontline workers received anti-corruption training in 2024.[3]

CSR in the chinese pharmaceutical industry

  • 36.77 RMB10,000 was spent by Sino Biopharmaceutical on rural revitalization in 2023.[16]
  • 2,026 mentions of “environment” appeared in 2020 CSR reports from Chinese pharmaceutical companies analyzed in a peer-reviewed study.[54]
  • 852.43 RMB10,000 was spent by Sino Biopharmaceutical on disaster relief in 2023.[16]
  • 35.40 RMB10,000 was spent by Sino Biopharmaceutical on epidemic-related support in 2023.[16]
  • 17.00 RMB10,000 was donated by Sino Biopharmaceutical to education in 2023.[16]

Circular economy in the chinese pharmaceutical industry

  • 22,482 tonnes of total Scope 1 and Scope 2 greenhouse-gas emissions were reported by TOT BIOPHARM in 2024.[1]
  • 0.20 tonnes of CO2e per RMB10,000 of revenue was TOT BIOPHARM’s 2024 emissions intensity, down 90% from its 2021 base year.[1]
  • 317 suppliers of China Shineway were assessed for environmental impact in 2024.[3]
  • 3,389 tonnes of Scope 1 greenhouse-gas emissions were reported by TOT BIOPHARM in 2024 in China.[1]
  • 19,093 tonnes of Scope 2 greenhouse-gas emissions were reported by TOT BIOPHARM in 2024 in China.[1]

Carbon footprint in the chinese pharmaceutical industry

  • 5,695.43 tonnes of Scope 1 CO2e emissions were reported by Ascentage Pharma in 2024.[41]
  • 7,776.66 tonnes of Scope 2 CO2e emissions were reported by Ascentage Pharma in 2024.[41]
  • 19,093 tonnes of Scope 2 CO2e emissions were generated by TOT BIOPHARM in 2024.[1]
  • 13,472.09 tonnes of combined Scope 1 and Scope 2 CO2e emissions were reported by Ascentage Pharma in 2024.[41]
  • 3,389 tonnes of Scope 1 CO2e emissions were generated by TOT BIOPHARM in 2024.[1]

14 Statistics

Globalization & Expansion

Globalization in the chinese pharmaceutical industry

  • Biocytogen had more than 1,800 research fellows working across four R&D centres in China and the United States in 2024.[3]
  • Jiangsu Hengrui Pharmaceuticals generated RMB3.47 billion in revenue from countries and regions outside mainland China in 2024.[1]
  • Jiangsu Hengrui Pharmaceuticals generated RMB4.77 billion in revenue from countries and regions outside mainland China in 2025.[1]
  • 94 cross-border out-licensing agreements involving Chinese drugmakers were recorded in 2024, with disclosed value of US$51.9 billion.[77]
  • 70 out-licensing deals were signed by Chinese companies in 2024, generating total disclosed value of US$40 billion and US$4.2 billion in upfront payments.[28]

Cultural adaptation in the chinese pharmaceutical industry

  • 26 overseas generic-drug varieties were submitted for launch approval by the reporting group in 2024, alongside 55 domestic varieties.[1]
  • 222 formal overseas patent applications were submitted by Biocytogen in 2024, compared with 57 formal patent applications in China.[3]
  • 10 or more oncology treatment fields were covered by Hengrui’s studies selected for presentation at the 2025 ASCO meeting.[3]
  • 14 countries and regions outside mainland China were covered by Hengrui’s overseas issued-patent portfolio at the end of 2025, including Europe, the United States and Japan.[3]
  • 20 of the 39 patents in the 2025 global patent portfolio of the reporting company covered overseas jurisdictions including the United States, Canada, Australia, Japan, Korea, Singapore, India and Europe.[3]

Supplier management in the chinese pharmaceutical industry

  • 100% of Biocytogen’s major suppliers were assessed in 2024 for quality, service and price performance, according to the company’s annual report.[25]
  • Approximately 2,150 suppliers supported Biocytogen at December 31, 2024, including more than 2,000 suppliers based in China.[25]
  • 66 licensed invention-patent authorizations were obtained by the reporting group’s pharmaceutical manufacturing segment in 2024, supporting its technology-supplier and licensing ecosystem.[1]
  • 180 drug clinical-trial approvals were secured by Hengrui in 2025, reflecting the scale of its external clinical and research operating relationships.[3]
  • More than 93% of Biocytogen’s suppliers were based in China at December 31, 2024, calculated from approximately 2,150 total suppliers and more than 2,000 Chinese suppliers.[25]

Stakeholder management in the chinese pharmaceutical industry

  • 220 patents were applied for by the reporting group’s pharmaceutical manufacturing segment in 2024, including applications in the United States and under the PCT system.[1]
  • More than 1,800 research fellows were employed by Biocytogen across four R&D centres in China and the United States in 2024.[3]
  • 3 customers each accounted for at least 10% of Hengrui’s revenue in 2025, with reported revenue of RMB8.17 billion, RMB3.75 billion and RMB3.25 billion respectively.[1]
  • 46 Hengrui oncology studies were selected for the 2025 ESMO Congress, including 4 late-breaking abstracts and 9 oral presentations.[3]
  • 18 of Hengrui’s 2025 recognized research papers had an impact factor of at least 30 in oncology or 20 in non-oncology fields.[3]

Distribution channels in the chinese pharmaceutical industry

  • 5.6% was the compound annual growth rate of China’s three major pharmaceutical terminals across six markets from 2013 to 2022.[25]
  • 9.2% was the share of China’s public primary-healthcare-institution terminal in pharmaceutical sales in 2022.[25]
  • 80% of China’s prescription-drug market was distributed through in-hospital channels in 2024, compared with 20% through out-of-hospital channels.[25]
  • 20% of China’s prescription-drug market was distributed through out-of-hospital channels in 2024.[25]
  • 29% was the share of China’s retail-pharmacy terminal in pharmaceutical sales in 2022.[25]
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Chinese Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/chinese-pharmaceutical-industry-statistics
MLA
Samuel Norberg. "Chinese Pharmaceutical Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/chinese-pharmaceutical-industry-statistics.
Chicago
Samuel Norberg. 2026. "Chinese Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/chinese-pharmaceutical-industry-statistics.

Sources & references

86 sources cited across this report

  1. www1.hkexnews.hk
  2. csis-website-prod.s3.amazonaws.com
  3. hkexnews.hk
  4. assets.kpmg.com
  5. ispe.org
  6. ppd.com
  7. pmlive.com
  8. test.benchling.com
  9. techresearchinfo.com
  10. benchling.com
  11. deloitte.com
  12. insights.indegene.com
  13. pharmamanufacturing.com
  14. 360storage.hkej.com
  15. english.www.gov.cn
  16. financialfilings.com
  17. links.sgx.com
  18. pmc.ncbi.nlm.nih.gov
  19. cisema.com
  20. veeva.com
  21. capgemini.com
  22. pistoiaalliance.org
  23. resources.indegene.com
  24. manu55.magtech.com.cn
  25. static.cninfo.com.cn
  26. sec.gov
  27. hengrui.com
  28. pharmadj.com
  29. zs.gov.cn
  30. english.shanghai.gov.cn
  31. globalforum.diaglobal.org
  32. ascentagepharma.com
  33. mckinsey.com
  34. innovatebio.org
  35. jthelander.com
  36. naceweb.org
  37. massbio.org
  38. biobuzz.io
  39. cultureamp.com
  40. amneal.com
  41. cdn.yahoofinance.com
  42. vip.stock.finance.sina.com.cn
  43. dt-consulting.com
  44. scirp.org
  45. people.5cy.com
  46. salesforce.com
  47. jamanetwork.com
  48. brand-news.it
  49. sermo.com
  50. jksb.com.cn
  51. cnpharm.com
  52. cpi.ac.cn
  53. pubmed.ncbi.nlm.nih.gov
  54. frontiersin.org
  55. glginsights.com
  56. iqvia.com
  57. richmondfed.org
  58. deallus.com
  59. valueinhealthjournal.com
  60. nature.com
  61. en.cdf.org.cn
  62. gtlaw.com
  63. sinobiopharm.com
  64. portal.s1.spglobal.com
  65. journals.plos.org
  66. money.finance.sina.com.cn
  67. nmpa.gov.cn
  68. lifesciencesny.org
  69. middlemarketcenter.org
  70. acrohealth.org
  71. fortinet.com
  72. cpl.thalesgroup.com
  73. etla.fi
  74. openpharma.blog
  75. kiteworks.com
  76. insights.economistenterprise.com
  77. caixinglobal.com
  78. euromonitor.com
  79. pdf.dfcfw.com
  80. yplt.mofcom.gov.cn
  81. english.beijing.gov.cn
  82. cphi.com
  83. chambers.com
  84. english.nmpa.gov.cn
  85. itif.org
  86. miit.gov.cn